[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Orchestra BioMed Holdings, Inc. insider filing shows Chief Financial Officer Andrew Taylor reported a non-derivative purchase of 2,000 shares of the company on 08/25/2025 at a price of $2.55 per share. Following the transaction, the reporting person beneficially owned 482,788 shares. The Form 4 was filed by a single reporting person and bears the reporting person's signature dated 08/25/2025.
La comunicazione insider di Orchestra BioMed Holdings, Inc. indica che il Chief Financial Officer Andrew Taylor ha dichiarato l'acquisto non derivato di 2.000 azioni della societ脿 in data 25/08/2025 al prezzo di $2,55 per azione. Dopo l鈥檕perazione, la persona che ha presentato la dichiarazione deteneva beneficiariamente 482.788 azioni. Il Modulo 4 猫 stato presentato da un unico soggetto dichiarante e porta la sua firma in data 25/08/2025.
El informe de informaci贸n privilegiada de Orchestra BioMed Holdings, Inc. muestra que el director financiero Andrew Taylor notific贸 la compra no derivada de 2.000 acciones de la compa帽铆a el 25/08/2025 a un precio de $2,55 por acci贸n. Tras la transacci贸n, la persona informante pose铆a beneficiariamente 482.788 acciones. El Formulario 4 fue presentado por una sola persona informante y lleva su firma con fecha 25/08/2025.
Orchestra BioMed Holdings, Inc.鞚� 雮措秬鞛� 瓿奠嫓鞐� 霐半ゴ氅� 斓滉碃鞛毂呾瀯鞛�(CFO) Andrew Taylor臧� 2025-08-25鞐� 須岇偓 欤检嫕 2,000欤茧ゼ 欤茧嫻 $2.55鞐� 牍勴寣靸�(non-derivative)鞙茧 毵れ垬頃� 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�. 頃措嫻 瓯半灅 頉� 氤搓碃鞛愲姅 鞁れ鞝侅溂搿� 482,788欤茧ゼ 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. Form 4電� 雼澕 氤搓碃鞚胳澊 鞝滌稖頄堨溂氅� 氤搓碃鞚胳潣 靹滊獏鞚� 2025-08-25搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
La d茅claration d'initi茅 d'Orchestra BioMed Holdings, Inc. indique que le directeur financier Andrew Taylor a d茅clar茅 un achat non d茅riv茅 de 2 000 actions de la soci茅t茅 le 25/08/2025 au prix de 2,55 $ par action. 脌 l'issue de la transaction, la personne d茅clarante d茅tenait 脿 titre b茅n茅ficiaire 482 788 actions. Le formulaire 4 a 茅t茅 d茅pos茅 par une seule personne d茅clarante et porte sa signature dat茅e du 25/08/2025.
Die Insider-Meldung von Orchestra BioMed Holdings, Inc. weist aus, dass Finanzvorstand Andrew Taylor am 25.08.2025 einen nicht-derivativen Kauf von 2.000 Aktien des Unternehmens zu einem Preis von $2,55 je Aktie meldete. Nach der Transaktion besa脽 die meldende Person wirtschaftlich 482.788 Aktien. Das Formular 4 wurde von einer einzelnen meldenden Person eingereicht und tr盲gt die Unterschrift der meldenden Person vom 25.08.2025.
- Reported non鈥慸erivative purchase of 2,000 shares on 08/25/2025 at $2.55 per share
- Filing discloses resulting beneficial ownership of 482,788 shares and is signed by the reporting person
- None.
Insights
TL;DR: CFO reported a small open-market purchase of 2,000 shares at $2.55, raising reported beneficial ownership to 482,788 shares.
The filing documents a straightforward, non鈥慸erivative acquisition by the Chief Financial Officer on 08/25/2025. The disclosed purchase size is modest relative to total reported beneficial ownership, and no derivative transactions or dispositions are reported. The disclosure is routine for insiders and provides a clear, dated record of the transaction and post鈥憈rade ownership.
TL;DR: Routine Section 16 filing: officer purchase recorded with signature and standard disclosures.
The Form 4 includes required elements: reporter identity and address, officer title (Chief Financial Officer), transaction date, transaction code (P for purchase), number of shares acquired, acquisition price, and resulting beneficial ownership. There are no amendments, joint filings, or complex plan indicators noted. The filing meets routine compliance expectations.
La comunicazione insider di Orchestra BioMed Holdings, Inc. indica che il Chief Financial Officer Andrew Taylor ha dichiarato l'acquisto non derivato di 2.000 azioni della societ脿 in data 25/08/2025 al prezzo di $2,55 per azione. Dopo l鈥檕perazione, la persona che ha presentato la dichiarazione deteneva beneficiariamente 482.788 azioni. Il Modulo 4 猫 stato presentato da un unico soggetto dichiarante e porta la sua firma in data 25/08/2025.
El informe de informaci贸n privilegiada de Orchestra BioMed Holdings, Inc. muestra que el director financiero Andrew Taylor notific贸 la compra no derivada de 2.000 acciones de la compa帽铆a el 25/08/2025 a un precio de $2,55 por acci贸n. Tras la transacci贸n, la persona informante pose铆a beneficiariamente 482.788 acciones. El Formulario 4 fue presentado por una sola persona informante y lleva su firma con fecha 25/08/2025.
Orchestra BioMed Holdings, Inc.鞚� 雮措秬鞛� 瓿奠嫓鞐� 霐半ゴ氅� 斓滉碃鞛毂呾瀯鞛�(CFO) Andrew Taylor臧� 2025-08-25鞐� 須岇偓 欤检嫕 2,000欤茧ゼ 欤茧嫻 $2.55鞐� 牍勴寣靸�(non-derivative)鞙茧 毵れ垬頃� 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�. 頃措嫻 瓯半灅 頉� 氤搓碃鞛愲姅 鞁れ鞝侅溂搿� 482,788欤茧ゼ 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. Form 4電� 雼澕 氤搓碃鞚胳澊 鞝滌稖頄堨溂氅� 氤搓碃鞚胳潣 靹滊獏鞚� 2025-08-25搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
La d茅claration d'initi茅 d'Orchestra BioMed Holdings, Inc. indique que le directeur financier Andrew Taylor a d茅clar茅 un achat non d茅riv茅 de 2 000 actions de la soci茅t茅 le 25/08/2025 au prix de 2,55 $ par action. 脌 l'issue de la transaction, la personne d茅clarante d茅tenait 脿 titre b茅n茅ficiaire 482 788 actions. Le formulaire 4 a 茅t茅 d茅pos茅 par une seule personne d茅clarante et porte sa signature dat茅e du 25/08/2025.
Die Insider-Meldung von Orchestra BioMed Holdings, Inc. weist aus, dass Finanzvorstand Andrew Taylor am 25.08.2025 einen nicht-derivativen Kauf von 2.000 Aktien des Unternehmens zu einem Preis von $2,55 je Aktie meldete. Nach der Transaktion besa脽 die meldende Person wirtschaftlich 482.788 Aktien. Das Formular 4 wurde von einer einzelnen meldenden Person eingereicht und tr盲gt die Unterschrift der meldenden Person vom 25.08.2025.
FAQ
What transaction did OBIO CFO report on the Form 4?
How many Orchestra BioMed (OBIO) shares does the reporting person beneficially own after the transaction?
Who filed the Form 4 for OBIO and what is their role?
When was the transaction executed and when was the Form 4 signed?
Did the Form 4 report any derivative transactions or dispositions?
